Article Sidebar

Download
PDF

Main Article Content

Abstract

 Les composés bioactifs des épices potentiellement antioxydant, hypoglycémiant et hypolipidémiant sont considérés comme des facteurs nutritionnels de choix dans la stratégie de prévention du syndrome métabolique (Smet). Le but de cette étude était d’évaluer les propriétés antihyperglycémiante, antihyperlipidémiante et antilipoperoxydative des extraits hydroéthanoliques (EHE) de trois épices locales : Aframomum aulacocorpus, Aframomum citratum et Aframomum daniellii. L’EHE d’A.daniellii a été plus actif pour l’inhibition des activités amylasique (99,19%) et invertasique (94,68%) comparé aux autres extraits (p<0,05) tandis que l’EHE d’A.aulacocorpus a significativement inhibé la lipase (93,33%). Les tests aigus ont montré que l’EHE d’A.aulacocorpus avait un effet antihyperlipidémiant important (77% ; p<0,05) alors que l’effet antihyperglycémiant était plus élevé avec l’EHE d’A.daniellii (78,48%) (p<0,05).

Keywords

Aframomum antioxydant hypoglycémiant hypolipidémiant syndrome métabolique.

Article Details

How to Cite
Nguélé, L., Fokunang, C., & Etoundi, C. (2013). CONTROLE DE QUELQUES COMPOSANTES DU SYNDROME METABOLIQUE PAR DES EXTRAITS HYDROETHANOLIQUES D’AFRAMOMUM AULACOCORPUS, A.CITRATUM ET A.DANIELLII (HOOK.F) K.SCHUM. HEALTH SCIENCES AND DISEASE, 13(3). https://doi.org/10.5281/hsd.v13i3.102
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome—a new Worldwide définition. Lancet 2005;366:1059-62.
  2. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet. Med. 2006 Mai; 23(5):469-480. ou http://www.idf.org/webdata/docs/IDF_Metasyndrome_definition.pdf, December 2006.
  3. Benzie, I. & Strain, J. (1996). The Ferric Reducing Ability of plasma (FRAP) as a measure of antioxydant power : The FRAP assay. Anal. Biochem., 239, 70-76.
  4. Cameron AJ, Magliano DJ, Zimmet PZ, Welborn TA, Colagiuri S, Tonkin AM, Shaw JE. The metabolic syndrome as a tool for predicting future diabetes: the AusDiab study. J. Intern. Med. 2008 Aoû; 264(2):177-186.
  5. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in Worldwide populations. Endocrinol.Metab Clin.North Am. 2004;33:351-75, table.
  6. Davy BM, Melby CL. The effect of fiber-rich carbohydrates on features of Syndrome X. J Am Diet.Assoc 2003;103:86-96.
  7. Desroches S, Lamarche B. The evolving définitions and increasing prevalence of the metabolic syndrome. Appl.Physiol Nutr Metab 2007;32:23-32.
  8. Dhandapani, R. (2007). Hypolipidemic activity of Eclipta prostrata leaf extract in atherogenic diet induced hyperlipidemic rats. Indian J. of Experim. Biol., 45, 617-619.
  9. Fossati, P. and Principe, L. (1982). Serum triglycerides determined colorimetrically with an enzyme that pro- duces hydrogen peroxide. Clin. Chem., 28, 2077-2080.
  10. Gorinstein, S., Zachwieja, Z., Katrich, E., Pawelszik, E., Hauekit, RR., Trakhtenaerg, S., Martin Belloso, O. (2004).
  11. Comparison of the Contents of the main antioxidant compounds and the antioxidant activity of white grapefruit and the new hyrid. Lebensm-wiss.u.Technol., 37 :337-343.
  12. Grundy SM, Abate N, Chandalia M. Diet composition and the metabolic syndrome: what is the optimal fat intake? Am J Med 2002; 113 Suppl 9B:25S-9S.
  13. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735-52.
  14. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005 Oct 25; 112(17):2735-2752.
  15. Grundy SM. Atherogenic dyslipidemia associated with metabolic syndrome and insulin résistance. Clin Cornerstone. 2006;8 Suppl ES21-S27.
  16. Grundy SM. Drug therapy of the metabolic syndrome: mmimizing the emerging crisis in polypharmacy. Nat.Rev.Drug Discov. 2006;5:295-309.
  17. Grundy, SM. (1998). Statin trials and goals of cholesterol-lowering therapy. Circulation, 97, 1436-1439.
  18. Kim HJ, Lee JS, Kim CK. Effect of exercise training on muscle glucose transporter 4 protein and intramuscular lipid content in elderly men with impaired glucose tolerance. Eur. J. Appl. Physiol. 2004 Déc; 93(3):353-358.
  19. Obiro, WC., Zhang, T., Jrang, B. (2008). The nutraceutical role of the Phaseolus vulgaris α-amylase inhibitor, Br. J. Nutr., 100 (1) :1-12.
  20. Prior, RL., Wu, X., Schaich. (2005). Standardized methods for the determination of antioxidant capacity and phenolics in foods and dietary supplements. J. Agric. Food .Chem., 53 : 4290-4302.
  21. Reaven GM. The fourth musketeer from Alexandre Dumas to Claude Bernard. Diabetologia. 1995 Jan; 38(1):3-13.
  22. Shahidi, F. (2008). Antioxidants : extraction, identification, application and efficacy measurement. EJEAFche., 7 :3325-3330.
  23. Singleton, V. & Rossi, J. (1965). Colorimetry of total phenolics with phosphomolydic-phosphotungstic acid reagents. Am. J. Enol. Vitic., 16 :144-158.
  24. Wirfalt E, Hedblad B, Gullberg B et al. Food patterns and components of the metabolic syndrome in men and women: a cross-sectional study within the Malmo Diet and Cancer cohort. Am J Epidemiol 2001; 154:11 50-9

Most read articles by the same author(s)